Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients

Inclusion criteria

• Patient aged from 18 to 80 years and no gender preference;
• Diagnosis of CVT as confirmed on MRBTI/MRV or CT/CTV or DSA;
• Acute or subacute CVT from onset to door within 4 weeks;
• The treating clinician irrelevant to the study is of the opinion that the patient is appropriate for edoxaban or rivaroxaban;
• Patient or legally authorized representative is able to give written informed consent.

Exclusion criteria

• Patient refuse to take edoxaban or rivaroxaban to treat CVT;
• Pregnancy or breastfeeding women at the time of enrollment, or women who plan to get pregnant during study;
• Patient is anticipated to require invasive procedure (e.g. thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation;
• CVT secondary to central nervous system infection or severe head trauma;
• It is in the proliferative stage of malignant tumors currently or within 6 months of diagnosis;
• Bleeding diathesis or other contraindication to anticoagulation;
• Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use;
• Concomitant use of strong CYP3A4 or P-gp inhibitors;
• Impaired renal function (CrCl<30 mL/min using Cockcroft-Gault equation) or investigator anticipate the CrCl lower than 30 mL/min during study;
• Impaired liver function (ALT or AST exceeds twice the normal upper limit) or diagnosed as acute hepatitis currently;
• Patient is unable to swallow due to depressed level of consciousness or other reasons;
• Patient has a severe or fatal comorbid illness with life expectancy less than 6 months;
• Patient with severe hypertension (SBP≥180mmHg and/or DBP≥110mmHg);
• Patient is known to be allergic to edoxaban or rivaroxaban.